BBI-3000, a completely novel potent topical/oral rexinoid, is currently in the pre-clinical stage of development for the treatment of acne.  

In preclinical studies performed by Brickell, BBI-3000 displayed activity that differentiated it from the leading topical retinoids currently available on the market. In medical dermatology, topical retinoids are typically indicated for treatment of acne and/or psoriasis and are available on the market as monotherapy or combination therapy.